EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of new K ir 2.1 channel openers from propafenone analogues

Encan Li iD, Najla Boujeddaine, Marien J C Houtman, Renee G C Maas, Joost P G Sluijter iD, Gerhard F Ecker iD, Anna Stary-Weinzinger iD, Willem B van Ham iD, Marcel A G van der Heyden iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Encan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Potassium Channels, Inwardly Rectifying, Propafenone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Health Holland EV-Protect.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purposes Reduced inward rectifier potassium channel (K ir 2.1) functioning is associated with heart failure and may cause Andersen‐Tawil Syndrome, among others characterized by ventricular arrhythmias. Most heart failure or Andersen–Tawil Syndrome patients are treated with β‐adrenoceptor antagonists (β‐blockers) or sodium channel blockers; however, these do not specifically address the inward rectifier current (I K1 ) nor aim to improve resting membrane potential stability. Consequently, additional pharmacotherapy for heart failure and Andersen–Tawil Syndrome treatment would be highly desirable. Acute propafenone treatment at low concentrations enhances I K1 current, but it also exerts many off‐target effects. Therefore, discovering and exploring new I K1 ‐channel openers is necessary. Experimental Approach Effects of propafenone and 10 additional propafenone analogues were analysed. Currents were measured by single‐cell patch‐clamp electrophysiology. K ir 2.1 protein expression levels were determined by western blot analysis and action potential characteristics were further validated in human‐induced pluripotent stem cells–derived cardiomyocytes (hiPSC‐CMCs). Molecular docking was performed to obtain detailed information on drug‐channel interactions. Key Results Analogues GPV0019, GPV0057 and GPV0576 strongly increased the outward component of I K1 while not affecting the K ir 2.1 channel expression levels. GPV0057 did not block I Kr at concentrations below 0.5 μmol L −1 nor Na V 1.5 current below 1 μmol L −1 . Moreover, hiPSC‐CMC action potential duration was also not affected by GPV0057 at 0.5 and 1 μmol L −1 . Structure analysis indicates a mechanism by which GPV0057 might enhance K ir 2.1 channel activation. Conclusion and Implications GPV0057 has a strong efficiency towards increasing I K1 , which makes it a good candidate to address I K1 deficiency‐associated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Potassium Channels, Inwardly RectifyingPropafenoneHumansMyocytes, CardiacMolecular Docking SimulationInduced Pluripotent Stem CellsHEK293 CellsAction Potentials

Stichwörter der Autor:innen

Kir2.1 channelcardiac pharmacologydrug discovery/target validationhiPSC‐CMCsion channelsoff‐target effectspropafenone analogues

Substanzen

Potassium Channels, Inwardly RectifyingPropafenoneKir2.1 channelKCNJ2 protein, human

Autor:innen und Institutionen

  • Department of Medical Physiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Cardiology, Laboratory of Experimental Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Circulatory Health Research Center, Regenerative Medicine Center Utrecht, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
  • Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.

ORCID-Profile: Encan Li, Joost P G Sluijter, Gerhard F Ecker, Anna Stary-Weinzinger, Willem B van Ham, Marcel A G van der Heyden

Förderung

  • China Scholarship Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Health Holland EV-Protect
  • ZonMw
  • European Research Council

Zitieren

APA

Li, E., Boujeddaine, N., Houtman, M. J. C., Maas, R. G. C., Sluijter, J. P. G., Ecker, G. F., Stary-Weinzinger, A., van Ham, W. B., & van der Heyden, M. A. G. (2025). Development of new K ir 2.1 channel openers from propafenone analogues. British Journal of Pharmacology. https://doi.org/10.1111/bph.17377

Vancouver

Li E, Boujeddaine N, Houtman MJC, Maas RGC, Sluijter JPG, Ecker GF, et al. Development of new K ir 2.1 channel openers from propafenone analogues. British Journal of Pharmacology. 2025. doi:10.1111/bph.17377

BibTeX
@article{Li2025,
  author = {Li, Encan and Boujeddaine, Najla and Houtman, Marien J C and Maas, Renee G C and Sluijter, Joost P G and Ecker, Gerhard F and Stary-Weinzinger, Anna and van Ham, Willem B and van der Heyden, Marcel A G},
  title = {Development of new K ir 2.1 channel openers from propafenone analogues},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17377}
}
Kostenlos starten →